Experiments illustrate that the combination of SORAFENIB and DASATINIB has a synergistic effect on melanoma cell line A2058, and inhibition of BRAF and KIT, the corresponding targets of SORAFENIB, reduces melanoma cell proliferation (Quattrini et al. 2019, Wang et al. 2021). Here, KIT is linked to melanoma.